Differences in reimbursement listing of anticancer therapies in China: an observational study

OBJECTIVE: Access to highly priced anticancer medications usually requires insurance coverage. A first step towards coverage of such medications is their inclusion in reimbursement lists. We assessed listing for reimbursement in China between 2009 and 2018 of anticancer medications on the WHO’s Esse...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiaodong, Zhang, Yichen, Wushouer, Haishaerjiang, Shi, Luwen, Ross-Degnan, Dennis, Wagner, Anita Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955534/
https://www.ncbi.nlm.nih.gov/pubmed/31911513
http://dx.doi.org/10.1136/bmjopen-2019-031203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955534/
https://www.ncbi.nlm.nih.gov/pubmed/31911513
http://dx.doi.org/10.1136/bmjopen-2019-031203

Ejemplares similares